marianascaranti

Medical oncologist with a primary focus on gyn cancers - DASA. Former fellow @ICR_London @royalmarsden. Views are my own.

[marianascaranti @marianascarant1]

Very happy to see our review published today in @NatRevClinOncol ! A team effort by @udai_banerji @BanerjeeSusana @elenacojocaru86 https://t.co/zOB78gcFUQ
#folatereceptor #ovariancancer @ICR_London @royalmarsdenNHS

[marianascaranti @marianascarant1]

@elenacojocaru86 @royalmarsdenNHS @GustaveRoussy Well done my friend!

[marianascaranti @marianascarant1]

Secondary cytoreduction in ovarian cancer: a wrap-up! Our paper is out! @IJGConline

[LACOG - Latin American Cooperative Oncology Group @LACOG_group]

We would like to share with you that the LACOG 0233/GOG-3073 ROSELLA study included its first patient in Brazil on the Nove de Julho Hospital site, whose principal investigator is Dr. Mariana Scaranti (@marianascarant1)
@br_gynoncgroup
@GOG

[marianascaranti @marianascarant1]

Join us! Great opportunity to discuss about ovarian cancer! https://t.co/mOlvpuVwvp

[LACOG - Latin American Cooperative Oncology Group @LACOG_group]

Participe da programação de sábado do Best of ASCO 2023 - Edição Brasil, que irá ocorrer em São Paulo!

[OncoNews @PortalOnconews]

Os oncologistas @angelica_onco, @marianascarant1 e Eduardo Paulino, do @GBTG_EVA, discutem os estudos que marcaram o panorama da ginecologia oncológica no #ASCO21 - https://t.co/6mvyZbPcIM @ASCO #ONCOGINECOLOGIA #ONCONEWS #ONCONEWSnoASCO21

[HSL MedOnc Fellows @FellowsHsl]

Sarcomas enthusiasts ⏩ check out our recently published-case report! CIC-DUX4 rearranged uterine cervix round-cell sarcoma exhibiting near-... https://t.co/98HMQHxpoW @alinec_vieira @CamilaBragancaX @marianascarant1 @sciencedirect @hsiriolibanes

[marianascaranti @marianascarant1]

MEKi for low grade serous ovarian cancer: a wrap-up! https://t.co/jERe2Bck68

[marianascaranti @marianascarant1]

I couldn’t agree more!

[Mario M. Leitao, Jr @leitaomd]

We MUST do all possible to reduce the burden on women of this disease. Not just vaccine but also better screening outreach. Also eliminate will be tough as there are much less common non-HPV cervical cancers unfortunately.

[marianascaranti @marianascarant1]

Online first: A proof-of-concept study showing single-agent activity of a RAF–MEK inhibitor, administered in an intermittent schedule, across a wide range of RAS–RAF-driven cancers. Great team effort! @ICR_London @udai_banerji @royalmarsdenNHS @DrChristinaGuo #ovariancancer #KRAS

[udaibanerji @udai_banerji]

Published onlline https://t.co/UPgRww8XE9 Results of an academic phase I and basket expansion. Thank you to all patients, clinical fellows and research staff who worked together to make this happen. @ICR_London @royalmarsdenNHS @cancerBRC @ECMC_UK @ICR_DDU_IIT @ICR_CTSU

[marianascaranti @marianascarant1]

ILD can be challenging in early phase oncology clinical trials. Our paper sheds light on this adverse event ! Check it out!

[Clinical Cancer Research @CCR_AACR]

Check out a paper by #AACR20 clinical trials plenary session presenter, Juanita Lopez - Radiological patterns of drug induced interstitial lung disease (DILD) in early phase oncology clinical trials. https://t.co/GMnkr1tVF3

[marianascaranti @marianascarant1]

@DrAbhiPal @royalmarsdenNHS @ICR_London @DrABiondo @DrRajivNShinde @DrChristinaGuo @DrSachinkhurana @crescensdtiu @thubeena6 @JuliaLaiKwon Great Job , fabulous people!

[marianascaranti @marianascarant1]

@DrChristinaGuo Congrats! Great job!

[marianascaranti @marianascarant1]

@fastshop Comprei um presente para o dia das mães . O pedido não chegou e o SAC não me atende . Acionei o procon e vamos ver se agora resolvem ! Estou impressionada com a falta de respeito ao cliente.

[marianascaranti @marianascarant1]

@BanerjeeSusana @Ovacome @OvarianCancerUK @LadyGardenFnd Great presentation!

[HSL MedOnc Fellows @FellowsHsl]

In LMICs we don’t have many opportunities for engaging with phase I trials. Glad that @marianascarant1 made this connection possible and @DrChristinaGuo could share some of her experience with us! #clinicalresearch #MedTwitter

[marianascaranti @marianascarant1]

Great tweetorial by a great mentor ! @udai_banerji #covid19

[udaibanerji @udai_banerji]

A WEEK IN THE LIFE OF AN ONCOLOGY CONSULTANT DURING THE COVID19 PANDEMIC. My first attempt at a tweetorial…. @ICR_London @royalmarsdenNHS @ICR_DDU_IIT @cancerBRC @ECMC_UK @CR_UK @NIHRresearch @NHSuk

[marianascaranti @marianascarant1]

Our paper on “Radiological patterns of DILD in early phase oncology clinical trials” is just out ! @udai_banerji @ICR_DDU_IIT @royalmarsdenNHS https://t.co/ZvG6rKdn1A

[marianascaranti @marianascarant1]

IceCAP dose escalation data soon to be present @AACR! Proof-of-concept evidence of immune modulation by blockade of the PI3K-AKT signaling pathway .

[ICR_DDU_IIT @ICR_DDU_IIT]

Our IceCAP study is now in its expansion phase; this is a Phase I study exploring the combination of Ipatasertib, an AKT inhibitor with Atezolizumab, a PD-L1 inhibitor, in advanced solid tumours and glioblastomas. Results of the escalation phase soon to be presented @AACR20

[marianascaranti @marianascarant1]

@AdrianaHepner @ASCO Congrats @AdrianaHepner !!!